{"article": [{"url": "https://stocknews.com/news/incy-chart-of-the-day-incyte-incy/", "published": 1595851700.0, "headline": "Chart of the Day: Incyte (INCY)", "body": "Incyte Corp. (INCY) has been trending higher since hitting its 52-week low on March 23rd. Yet, now the rally has stalled and a key resistance level has formed. INCY focuses on the discovery and development of small-molecule drugs. The company\u2019s lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease. The company last week announced positive results from a Phase 3 clinical trial, REACH3, that evaluated Jakafi in patients with moderate or severe steroid-refractory or steroid dependent chronic graft-versus-host disease (GvHD). Take a look at the 1-year chart of INCY below with added notations: 9 \"BUY THE DIP\" Growth Stocks For 2020 Chart of INCY provided by TradingView As you can see in the chart above, there is a resistance level that has formed at $110 (red) and was tested on three separate occasions. $110 is also the 52 week high for INCY. A trader could buy the stock after a solid close above the resistance level with the expectation of a breakout. Keep an eye out on August 4th for INCY\u2019s latest earnings report. Have a good trading day! Good luck! Christian Tharp, CMT @cmtstockcoach Want More Great Investing Ideas? 5 WINNING Stock Charts 9 \u201cBUY THE DIP\u201d Growth Stocks for 2020 Newly REVISED 2020 Stock Market Outlook 7 \u201cSafe-Haven\u201d Dividend Stocks for Turbulent Times INCY shares were trading at $101.95 per share on Monday morning, up $2.53 (+2.54%). Year-to-date, INCY has gained 16.75%, versus a 1.24% rise in the benchmark S&P 500 index during the same period."}]}